Top Globe News – Lifestyle
Author:
Castle Biosciences, Inc.
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
March 13, 2026
←
Previous Page
1
2